IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB

Journal of Clinical Investigation

Volumn 107, Issue 11, 2001, Pages 1375-1385

  Abu Amer, Yousef ^a,b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; OSTEOCLAST DIFFERENTIATION FACTOR; STAT6 PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA BINDING; ELECTROPHORETIC MOBILITY; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; OSTEOCLAST; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 0034992555     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10530     Document Type: Article

References (70)

1. Molecular mechanisms of bone resorption
2. Osteoclasts, macrophages, and the molecular mechanisms of bone resorption
3. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells
4. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures
5. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells
6. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its p55 receptor
7. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
8. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
9. Modulation of osteoclast differentiation by local factors
10. Regulation of osteoclast function
11. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
12. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
13. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor
14. Characterization of the intracellular domain of receptor activator of NF-κB (RANK)
15. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways
16. Osteopetrosis in mice lacking NFκB1 and NFκB2
17. NFκB and bone: The breaking point
18. NF-kappaB: A lesson in family values
19. NF-κB activation: The IκB kinase revealed?
20. NF-kappa B: Ten years after
21. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-κB
22. Identification and characterization of an IkappaB kinase
23. IKK1 and IKK2: Cytokine-activated IκB kinases essential for NF-κB activation
24. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1
25. Site-specific tyrosine phosphorylation of Ikappa;Balpha negatively regulates its inducible phosphorylation and degradation
26. Tumor necrosis factor-alpha activation of nuclear transcription factor-kappaB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of Ikappa Balpha
27. Interleukin-4, interferon gamma and prostaglandin E impact the osteoclast forming potential of murine bone marrow macrophages in vitro
28. Cytokine and bone remodeling
29. Short term treatment of recombinant IL-4 rapidly inhibits bone formation in normal and ovariectomized mice
30. Role of cytokines in bone resorption
31. 2+ in murine osteoclasts
32. Cytokines and acute phase proteins in rheumatoid arthritis
33. Th1-Th2: Reliable paradigm or dangerous dogma?
34. The IL-4 receptor: Signaling mechanisms and biologic functions
35. Evaluation of synovial cytokine patterns in rheumatoid arthritis and osteoarthritis by quantitative reverse transcription polymerase chain reaction
36. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis
37. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondy-larthropathies
38. Essential role of Stat6 in IL-4 signalling
39. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways
40. IL4 and IL13 receptors share the gamma c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells
41. STAT6 is required for the anti-inflammatory activity of interleukin-4 in mouse peritoneal macrophages
42. STAT6: Its role in interleukin 4-mediated biological functions
43. Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex-vivo model of bone resorption in RA
44. Effects of interleukin-4 on the formation of macrophages and osteoclast-like cells
45. Interleukin-4 modulates osteoclast differentiation and inhibits the formation of resorption pits in mouse osteoclast cultures
46. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis
47. Bone marrow-derived mononuclear phagocytes autoregulate mannose receptor expression
48. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
49. Tyrosine kinase inhibitors, genistein and herbimycin A, do not block interleukin-1 beta-induced activation of NF-kappa B in rat mesangial cells
50. Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages
51. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration
52. In vivo protein transduction: Delivery of a biologically active protein into the mouse
53. Protein transduction: Unrestricted delivery into all cells?
54. 3 gene
55. IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms
56. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease
57. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro
58. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells
59. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
60. Interleukin-4-induced macrophage fusion is prevented by inhibitors of mannose receptor activity
61. Interleukin-4 induces foreign body giant cells from human monocytes/macrophages. Differential lymphokine regulation of macrophage fusion leads to morphological variants of multinucleated giant cells
62. Interleukin-4 down-regulates both forms of tumor necrosis factor receptor and receptor-mediated apoptosis, NF-kappaB, AP-1, and c-Jun N-terminal kinase. Comparison with interleukin- 13
63. Interleukin 4 and human immunodeficiency virus stimulate LFA-1-ICAM-1-mediated aggregation of monocytes and subsequent giant cell formation
64. Mouse macrophage development in the absence of the common gamma chain: Defining receptor complexes responsible for IL-4 and IL-13 signaling
65. Interleukin-4 suppression of tumor necrosis factor alpha-stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF-kappaB
66. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
67. TAT fusion proteins containing dominant-negative IκB block osteoclastogenesis
68. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
69. IL-13 and IL-4 inhibit bone resorption by suppressing COX-2-dependent prostaglandin synthesis in osteoblasts
70. Analysis of signal transduction pathways regulating cytokine-mediated Fc receptor activation on human eosinophils